Rodriguez Nancy A, Meier Paula P, Groer Maureen W, Zeller Janice M, Engstrom Janet L, Fogg Lou
NorthShore University HealthSystem, Chicago, Illinois, USA.
Adv Neonatal Care. 2010 Aug;10(4):206-12. doi: 10.1097/ANC.0b013e3181e94133.
Own mother's colostrum is rich in cytokines and other immune agents that may stimulate oropharyngeal-associated lymphoid tissue if administered oropharyngeally to extremely low-birth-weight (ELBW) infants during the first days of life when enteral feeding is contraindicated. However, the safety and feasibility of the oropharyngeal route for the administration of colostrum have not been determined.
To determine the safety of oropharyngeal administration of own mother's colostrum to ELBW infants in first days of life. A secondary purpose was to investigate the feasibility of (1) delivering this intervention to ELBW infants in the first days of life and (2) measuring concentrations of secretory immunoglobulin A and lactoferrin in tracheal aspirate secretions and urine of these infants.
Five ELBW infants (mean birth weight and gestational age = 657 g and 25.5 weeks, respectively).
Quasi-experimental, 1 group, pretest-posttest design.
Subjects received 0.2 mL of own mother's colostrum administered oropharyngeally every 2 hours for 48 consecutive hours, beginning at 48 hours of life. Concentrations of secretory immunoglobulin A and lactoferrin were measured in tracheal aspirates and urine of each subject at baseline, at the completion of the intervention and again 2 weeks later.
All infants completed the entire treatment protocol, each receiving 24 treatments. A total of 15 urine specimens were collected and 14 were sufficient in volume for analysis. A total of 15 tracheal aspirates were collected, but only 7 specimens (47%) were sufficient in volume for analysis. There was wide variation in concentrations of secretory immunoglobulin A and lactoferrin in urine and tracheal aspirates among the 5 infants; however, several results were outside the limits of assay detection. All infants began to suck on the endotracheal tube during the administration of colostrum drops. Oxygen saturation measures remained stable or increased slightly during each of the treatment sessions. There were no episodes of apnea, bradycardia, hypotension, or other adverse effects associated with the administration of colostrum.
Oropharyngeal administration of own mother's colostrum is easy, inexpensive, and well-tolerated by even the smallest and sickest ELBW infants. Future research should continue to examine the optimal procedure for measuring the direct immune effects of this therapy, as well as the clinical outcomes such as infections, particularly ventilator-associated pneumonia.
母亲自身的初乳富含细胞因子和其他免疫因子,在出生后最初几天肠道喂养禁忌时,若对极低出生体重(ELBW)婴儿经口咽部给予初乳,可能会刺激口咽相关淋巴组织。然而,经口咽部给予初乳的安全性和可行性尚未确定。
确定出生后最初几天对ELBW婴儿经口咽部给予母亲自身初乳的安全性。次要目的是研究(1)在出生后最初几天对ELBW婴儿实施该干预措施的可行性,以及(2)测量这些婴儿气管吸出物和尿液中分泌型免疫球蛋白A和乳铁蛋白的浓度。
5名ELBW婴儿(平均出生体重和胎龄分别为657g和25.5周)。
准实验性、单组、前后测设计。
研究对象从出生48小时开始,每2小时经口咽部给予0.2mL母亲自身的初乳,连续给予48小时。在基线、干预结束时以及2周后,测量每名研究对象气管吸出物和尿液中分泌型免疫球蛋白A和乳铁蛋白的浓度。
所有婴儿均完成了整个治疗方案,每名婴儿接受了24次治疗。共收集了15份尿液标本,其中14份标本量足够进行分析。共收集了15份气管吸出物,但只有7份标本(47%)量足够进行分析。5名婴儿尿液和气管吸出物中分泌型免疫球蛋白A和乳铁蛋白的浓度差异很大;然而,有几个结果超出了检测范围。所有婴儿在滴入初乳期间开始吸吮气管内导管。每次治疗期间,血氧饱和度测量值保持稳定或略有升高。没有出现呼吸暂停、心动过缓、低血压或与给予初乳相关的其他不良反应。
对ELBW婴儿经口咽部给予母亲自身的初乳简便、廉价,即使是最小、病情最严重的ELBW婴儿也能很好耐受。未来的研究应继续探讨测量该疗法直接免疫效果的最佳方法,以及诸如感染,特别是呼吸机相关性肺炎等临床结局。